NCT05346484
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05346484
Title A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)
Acronym MAST
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Imugene Limited
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
University of Arizona Cancer Center Tucson Arizona 85724-5024 United States Details
Highlands Oncology Springdale Arkansas 72762 United States Details
City of Hope Medical Center Duarte California 91010 United States Details
UC San Diego Moores Cancer Center La Jolla California 92093-0698 United States Details
University of Miami Miami Florida 33136 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Corewell Health Grand Rapids Michigan 49503 United States Details
University of Cincinnati Cincinnati Ohio 45219 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
NEXT Oncology Fairfax Virginia 22031 United States Details
Tasman Oncology Research Southport Queensland 4215 Australia Details
St. Vincent's Hospital Fitzroy Victoria 3065 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field